SCHEMBL12009105

SCHEMBL12009105

Cc1cc(C(=O)O)ccc1-n1c(C)cc(C=C2SC(=O)N(c3ccccc3)C2=O)c1C

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 8/20 0.63
▸ KMT2A Q03164 10/20 0.61
▸ MEN1 O00255 9/20 0.61
▸ ALDH1A1 P00352 7/20 0.61
▸ MAPT P10636 6/20 0.61
▸ KDM4E B2RXH2 5/20 0.61
▸ L3MBTL1 Q9Y468 4/20 0.61
▸ TCF4 P15884 1/20 0.61
▸ CTNNB1 P35222 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ MYC P01106 2/20 0.56
▸ DUSP22 Q9NRW4 1/20 0.53
▸ RECQL P46063 3/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ APEX1 P27695 2/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ NR1H4 Q96RI1 1/20 0.48
▸ HTT P42858 3/20 0.48
▸ RAB9A P51151 4/20 0.47
▸ MAPK1 P28482 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18545456 1.00 POLB (0.63) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL12009106 0.91 TCF4 (0.57) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL12009113 0.89 TCF4 (0.61) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL18545440 0.88 TCF4 (0.65) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL12009063 0.88 TCF4 (0.65) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL18545596 0.88 TCF4 (0.68) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL12009043 0.88 TCF4 (0.68) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL12009077 0.87 POLB (0.79) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL18545611 0.87 POLB (0.79) POLBKMT2AMEN1ALDH1A1MAPT
SCHEMBL18545614 0.87 TCF4 (0.69) POLBKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF DASGUPTA RAMANUJ (US) 2017-02-23 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9433611-B2 Oxazole and thiazole compounds as β-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2016-09-06 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-9173871-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2015-11-03 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF NEW YORK UNIVERSITY 2013-05-02 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF UNITED STATES GOVERNMENT 2012-10-18 — — US disclosed
US-8252823-B2 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof NEW YORK UNIVERSITY (US) 2012-08-28 — — US disclosed
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof US ARMY, SECRETARY OF THE ARMY 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264744-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2397/4885KMT2A 4503/4885MEN1 3747/4885
US-20090227624-A1 Oxazole and thiazole compounds as beta-catenin modulators and uses thereof CTNNB1, CTNNA1, CTNNBL1 POLB 2088/4885KMT2A 4591/4885MEN1 4655/4885
US-20170049751-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2088/4885KMT2A 4591/4885MEN1 4655/4885
US-20130109675-A1 OXAZOLE AND THIAZOLE COMPOUNDS AS BETA-CATENIN MODULATORS AND USES THEREOF CTNNB1, CTNNA1, CTNNBL1 POLB 2088/4885KMT2A 4591/4885MEN1 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback